Because H2Mab-250 and trastuzumab are mouse IgG1 and human IgG1, respectively, we produced the human IgG1 type of recombinant H2Mab-250 (H2Mab-250-hG1) and trastuzumab and confirmed the reactivity against breast cancers and normal epithelial cells (Supplementary Figure S1). The gene discussed is PKD1P1; the disease is breast carcinoma.